168 related articles for article (PubMed ID: 2957818)
1. The resistance of fibrin-stimulated tissue plasminogen activator to inactivation by a class PAI-2 inhibitor (minactivin).
Leung KC; Byatt JA; Stephens RW
Thromb Res; 1987 Jun; 46(6):755-66. PubMed ID: 2957818
[TBL] [Abstract][Full Text] [Related]
2. Poly-D-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin).
Leung KC; Byatt JA; Stephens RW
Thromb Res; 1987 Jun; 46(6):767-77. PubMed ID: 3114909
[TBL] [Abstract][Full Text] [Related]
3. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
4. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
5. Fibrin induction of tissue plasminogen activator expression in corneal endothelial cells in vitro.
Ramsby ML; Kreutzer DL
Invest Ophthalmol Vis Sci; 1993 Oct; 34(11):3207-19. PubMed ID: 7691778
[TBL] [Abstract][Full Text] [Related]
6. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay.
Eriksson E; Rånby M; Gyzander E; Risberg B
Thromb Res; 1988 Apr; 50(1):91-101. PubMed ID: 3135638
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
8. The activation of plasminogen by T-PA-PAI-1 complex in the absence of fibrin.
Takada Y; Takada A
Thromb Res; 1991 Jul; 63(1):169-77. PubMed ID: 1835180
[TBL] [Abstract][Full Text] [Related]
9. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
[TBL] [Abstract][Full Text] [Related]
10. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
Félez J; Rueda F
Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250
[No Abstract] [Full Text] [Related]
12. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
13. Changes in various parameters of fibrinolysis in persons infused with tissue plasminogen activator: special reference to plasminogen activator inhibitor.
Takada A; Hou P; Mori T; Takada Y
Thromb Res Suppl; 1988; 8():23-33. PubMed ID: 3144766
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
Masson C; Angles-Cano E
Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes.
Levin RI; Harpel PC; Harpel JG; Recht PA
Blood; 1989 Oct; 74(5):1635-43. PubMed ID: 2529003
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
17. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
18. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
Weitz JI
J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.
Reilly CF; Hutzelmann JE
J Biol Chem; 1992 Aug; 267(24):17128-35. PubMed ID: 1512250
[TBL] [Abstract][Full Text] [Related]
20. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators.
Golder JP; Stephens RW
Eur J Biochem; 1983 Nov; 136(3):517-22. PubMed ID: 6416839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]